吸入用布地奈德混悬液治疗重症肺炎患儿的临床研究  

Clinical trial of budesonide inhalation suspension in the treatment of children with severe pneumonia

作　　者：李少澍[1] 黄志锋[1] 赖素贤[1] LI Shao-shu;HUANG Zhi-feng;LAI Su-xian(Department of Pediatrics,Quanzhou First Hospital Affiliated to Fujian Medical University,Quanzhou 362000,Fujian Province,China)

机构地区：[1]福建医科大学附属泉州第一医院儿科

出　　处：《中国临床药理学杂志》2019年第23期2978-2980,共3页The Chinese Journal of Clinical Pharmacology

基　　金：福建省卫生厅青年科研课题资助项目(2013-2-123)

摘　　要：目的观察吸入用布地奈德混悬液治疗重症肺炎患儿的临床疗效及安全性。方法将100例重症肺炎患儿随机分为对照组50例和试验组50例。对照组予以机械通气、化痰、解痉和抗感染治疗;试验组在对照组治疗的基础上,给予布地奈德雾化吸入治疗,每次2 mg,每次10~15 min,bid。2组患儿均治疗14 d。比较2组患儿的临床疗效,肺功能,以及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为96.00%(48例/50例)和86.00%(43例/50例),差异有统计学意义(P<0.05)。治疗后,试验组和对照组的第1秒用力呼气容积(FEV1)分别为(49.98±6.44)%和(45.94±7.12)%,FEV1/用力肺活量分别为(64.88±4.88)%和(55.69±9.80)%,氧分压分别为(70.06±7.52)和(65.02±6.33)mm Hg,二氧化碳分压分别为(44.94±5.23)和(54.06±5.88)mm Hg,差异均有统计学意义(均P<0.05)。2组患儿治疗期间均未发生药物不良反应。结论吸入用布地奈德混悬液治疗重症肺炎患儿的临床疗效较好,且安全性较高。Objective To observe the clinical efficacy and safety of budesonide suspension inhalation in the treatment of children with severe pneumonia.Methods A total of 100 children with severe pneumonia were randomly divided into control group and treatment group with 50 cases per group.Control group was treated with mechanical ventilation,expectoration,spasmolysis and anti-infective therapy.Treatment group received budesonide aerosol inhalation 2 mg per time with 10-15 minutes each time,bid,on the basis of control group.Two groups were treated for 14 days.The clinical efficacy,pulmonary function and adverse drug reactions were compared between two groups.Results After treatment,the total effective rates of treatment and control groups were 96.00%(48 cases/50 cases)and 86.00%(43 cases/50 cases)with significant difference(P<0.05).After treatment,the main indexes of treatment and control groups were compared:forced expiratory volume in one second(FEV1)were(49.98±6.44)%and(45.94±7.12)%,FEV1/forced vital capacity were(64.88±4.88)%and(55.69±9.80)%,partial pressure of oxygen were(70.06±7.52)and(65.02±6.33)mm Hg,and partial pressure of carbon dioxide were(44.94±5.23)and(54.06±5.88)mm Hg,the differences were statistically significant(all P<0.05).No adverse drug reactions occurred during the treatment in two groups.Conclusion Budesonide inhalation suspension has a definitive clinical efficacy and safety in the treatment of children with severe pneumonia.

关 键 词：吸入用布地奈德混悬液 重症肺炎 肺功能 安全性评估 

分 类 号：R974[医药卫生—药品]